Skip to Main Content
Skip Nav Destination


Blinatumomab

Basics

Name

Blinatumomab

Pronunciation

(blin a TOOM oh mab)

Brand Names: US

  • Blincyto

Therapeutic Category

  • Antineoplastic Agent, Anti-CD19/CD3
  • Antineoplastic Agent, Monoclonal Antibody

Medication Safety Issues

Sound-alike/look-alike issues:

Blinatumomab may be confused with belantamab mafodotin, bezlotoxumab, obinutuzumab

High alert medication

This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.

Other safety concerns

Preparation and administration errors have occurred. Do not flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose and complications. IV bag contains overfill and volume will be more than the volume administered to the patient to account for IV line priming and to ensure that the full dose is administered. Carefully follow preparation and administration instructions. Refer to manufacturer labeling for further information.

This item requires a subscription. For full access to this content, please log in to an existing user account or purchase an individual subscription. If you have an active subscription and appear logged in (your name appears in the upper right corner), but you cannot access content, please click the “Log Out” option under your name and log back in.
Close Modal

or Create an Account

Close Modal
Close Modal